Abstract

Fru is a highly selective, novel vascular endothelial growth factor receptor (VEGFR) -1, -2, and -3 tyrosine kinase inhibitor (TKI). In the ph 3 FRESCO study (NCT02314819) that led to its approval in China, Fru 5mg daily, 3 weeks (wks) on 1 wk off, improved the median overall survival in pts with mCRC in third line and beyond when compared to placebo (9.3 v 6.6 months); hazard ratio 0.65 (P < 0.001).

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call